Renascience Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Mar 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 15, 2027.
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,479 | Inhibitor of plasminogen activator inhibitor-1 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,785,473 | Plasminogen activator inhibitor-1 inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,092,537 | Use for PAI-1 inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 11,564,924 | Pharmaceutical composition formed by combining pyridoxamine compound and thiamine compound In force · From the USPTO record | In force | From the USPTO record | |
| US 11,253,519 | Composition Used to Improve Symptoms of Autism Spectrum Disorder, and Method Using Same for Improving Symptoms of Autism Spectrum Disorder In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 3 abandoned · 1 no status recorded
Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/561,497 | Method for Quantifying Phenylalanine in Blood, and Measurement Kit Used Therefor | May 17, 2022 | Pending |
| 17/925,750 | Drug for Enhancing Fibrinolytic System, and Use Therefor | May 20, 2021 | Pending |
| 17/764,312 | Inhibitor Against Expression of Immune Checkpoint Molecule | Sep 30, 2020 | Pending |
| 17/441,484 | Orally Active Small Molecule Inhibitor of PAI-1 | Mar 20, 2020 | Pending |
| 16/611,064 | Recombinant Microorganism and Method of Producing Pyridoxamine or Salt Thereof Using Recombinant Microorganism | May 11, 2018 | Abandoned |
| 16/611,053 | Recombinant Microorganism, Method of Producing Pyridoxamine or Salt Thereof Using Recombinant Microorganism, and Method of Producing Pyridoxal or Salt Thereof Using Recombinant Microorganism | May 11, 2018 | Abandoned |
| 14/325,808 | Detection and Treatment of Schizophrenia | Jul 8, 2014 | Abandoned |
| 14/307,149 | Jun 17, 2014 | No status recorded |